Turku-based Pharmatest Services Ltd participated in an international project with promising results
The Turku-based company Pharmatest Services Ltd has identified 15 new compounds suitable for breast and prostate cancer drugs. The compounds were identified with newly developed methods using cancer cell lines that allow decreasing considerably animal testing in future cancer drug development.
The Turku-based company Pharmatest Services Ltd participated in a 3-year research project “DISC-SCREEN” funded by the Eurostars program of EU. In the project Pharmatest developed new testing methods where cancer cell lines are used for estimating efficacy of cancer drug candidates. Pharmatest was able to use the methods for identifying 15 patentable drug candidates from a large group of compounds modeled in silico by the Romanian partner CCTI:n (Centrul Pentru Cooperare Tehnologica si Industriala) and synthesized by the Spanish partner IUCT:n (Institut Universitari De Ciència I Tecnologia). The compounds were more efficient and safer than the best cancer drugs currently on the markets when tested in various breast and prostate cancer cell lines.
Pharmatest, IUCT and CCTI have started negotiations with a drug development company for utilizing and patenting the results. The companies predict to start more detailed preclinical tests with 3-5 compounds within the next three months and get at least one compound to clinical studies within the next two years.